LAUNXP Biomedical Co., Ltd

NT$14.00As of Sun 8 Nov 2026, 12:00 UTC

TPEx:6876Healthcare

Country Taiwan

PE (Fwd) 132.6

TSR 3Y CAGR (19.97%)

Div yield —

ROE —

Biotechnology

Beta (5Y) —

PE TTM —

TSR TTM (36.22%)

Mkt cap NT$987.4M

ROIC —

SE Grade™

—

Value

—

Quality

—

Moat

1Y Price

Reference

NT$15

—

5.36%

—

TTM

FYE 31 Dec TWD

FY2021

FY2022

FY2023

FY2024

FY2025

FY2026E

Trend

10Y

Peers

—

RevenueNT$M

—

◌—

0.011

2.484

—

3.513

22481.82%

—

Revenue growth%

—

22481.82

—

41.42

22481.82

—

Gross margin%

—

◌—

91.99

—

91.99

—

Operating margin%

—

(736809.09)

(3313.37)

—

91.99

(370061.23)

—

Net margin%

—

(735900.00)

(3325.08)

—

100.00

(369612.54)

—

P/E ratio (avg)x

—

157.7

—

EV/EBITx

—

139.5

—

FCF yield (avg)%

—

(10.27)

—

0.63

(10.27)

—

FCF margin%

—

(567745.45)

(3098.79)

—

100.00

(285422.12)

—

FCF / Net incomex

—

0.957

1.032

0.771

0.932

—

1.000

0.944

—

ROIC%

—

(96.08)

(186.30)

(965.44)

(861.24)

—

25.04

(523.77)

—

Return on equity%

—

(53.27)

(99.75)

(78.78)

(56.54)

—

3.03

(67.66)

—

Return on assets%

—

(47.03)

(134.43)

(39.20)

(66.66)

—

2.68

(56.85)

—

EPSNT$

—

(2.42)

(3.44)

(2.56)

—

0.09

—

EPS growth%

—

(42.13)

25.47

—

(8.33)

—

Bookvalue per shNT$

—

1.23

7.79

3.38

—

2.93

65.56%

—

FCF per shareNT$

—

(2.50)

(2.65)

(2.39)

—

0.09

—

Dividend per shNT$

—

Div yield (avg)%

—

Payout ratio%

—

70.53

Shares (diluted)M

—

18.02

23.54

32.22

39.56

◌39.56

29.97%

—

(22.79)

Buyback yield%

—

(30.59)

(36.91)

(22.79)

◌—

(30.59)

—

D/E ratiox

—

0.079

0.161

0.014

0.022

—

0.021

0.050

—

987.4

Enterprise valueNT$M

—

653.9

861.8

450.9

31.80%

—

LT debtNT$M

—

Peers (US$12.30M)

Cap (US$)

SynCore Biotechnology…

16.78M

—

TaiwanJ Pharmaceutical…

14.62M

—

Vectorite Biomedical…

14.28M

4.021x

Fractyl Health, Inc.

12.33M

—

Capital

TTM

10Y

Leveragex

—

EBIT/Intx

—

(532.9)

Own earn%

—

Sh yield%

(22.79)

(30.59)

Owners

Insiders/Inst%

2.58

6.94

Short interest%

—

SBC / revenue%

—

Record

10Y

Profitable years

0/4

Revenue growth years

—

EPS growth years

—

Dividend streakyrs

Op margin range%

—

$1 testx

—

Incr. ROIC%

—

LAUNXP Biomedical Co., Ltd engages in the research and development of drugs for cancer patients. It develops various drugs, which are in preclinical stage, including LXP5948 for non-small cell lung cancer and Alzheimer's disease; LXP5268 for triple negative breast cancer; LXP5101 for pancreatic cancer; LXP1788 for gastrointestinal cancer; and Virus-like particles for cancer and genetic defect treatment.

Revenue by segment

No breakdown available

Revenue by region

No breakdown available

Reinvestment returns

No breakdown available